RE:30 mill to 20 mill cost projection./ Approvals before Dec.I wouldn't get too excited over this management's forecasts. They are the same people that predicted a $50 million a year revenue stream from the cell sensing technology of the TLC-2000. I still remember RW saying in an interview that by year end 2018 they would be expecting commercial approval of their cancer science. Suddenly $10 million disappears in the cost of the NMIBC trial. Investors don't what to believe anymore. The CFO has to get her act together if this company is to be taken seriously.